GlassScriptPhysician profile
Rachel C Toney
NPI 1225189780
$408.11
in general payments reported to CMS, 2019-2025
11 companies · $86.12 in 2025
The $86.12 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.81 · 2023: $48.85 · 2024: $255 · 2025: $86.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $390.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $120.02 | 2024 | Prolastin-C Liquid |
| Abbvie INC. | $50.77 | 2025 | |
| Phathom Pharmaceuticals, INC. | $41.95 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $37.60 | 2023-2024 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $29.64 | 2023 | Linzess |
| Glaxosmithkline, LLC. | $28.13 | 2024 | |
| Genzyme Corporation | $27.52 | 2024 | |
| Pfizer INC. | $24.55 | 2024 | |
| Covidien LP | $17.81 | 2020 | |
| Janssen Biotech, INC. | $15.84 | 2025 | Tremfya |
| Xeris Pharmaceuticals, INC. | $14.28 | 2024 | Keveyis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Toney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.